Department of Surgery, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
Department of Pediatrics, University of California San Diego, La Jolla, California, United States.
Am J Physiol Gastrointest Liver Physiol. 2023 Jul 1;325(1):G42-G61. doi: 10.1152/ajpgi.00017.2023. Epub 2023 May 2.
The use of probiotics, prebiotics, and synbiotics has become an important therapy in numerous gastrointestinal diseases in recent years. Modifying the gut microbiota, this therapeutic approach helps to restore a healthy microbiome. Nonalcoholic fatty liver disease and alcohol-associated liver disease are among the leading causes of chronic liver disease worldwide. A disrupted intestinal barrier, microbial translocation, and an altered gut microbiome metabolism, or metabolome, are crucial in the pathogenesis of these chronic liver diseases. As pro-, pre-, and synbiotics modulate these targets, they were identified as possible new treatment options for liver disease. In this review, we highlight the current findings on clinical and mechanistic effects of this therapeutic approach in nonalcoholic fatty liver disease and alcohol-associated liver disease.
近年来，益生菌、益生元和合生元的使用已成为许多胃肠道疾病的重要治疗方法。这种治疗方法通过改变肠道微生物群来帮助恢复健康的微生物组。非酒精性脂肪性肝病和酒精相关性肝病是全球导致慢性肝病的主要原因之一。肠道屏障的破坏、微生物易位以及肠道微生物组代谢或代谢组的改变在这些慢性肝病的发病机制中起着关键作用。由于益生菌、益生元和合生元可以调节这些靶点，因此它们被认为是肝病的潜在新治疗选择。在这篇综述中，我们重点介绍了这种治疗方法在非酒精性脂肪性肝病和酒精相关性肝病中的临床和机制作用的最新发现。
